Our Transitions: Improving the Path to Menopause With Personal Digital Health Technologies

NCT07597915 | Not Yet Recruiting

• 1 other identifier: PRO-OT2025
• Study Type: observational
• Target: 1,250
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this observational study is to build knowledge about the path to menopause using subjective, self-reported and objectively measured information from multiple wearable study devices and a smartphone app. This study is being done in female individuals who are 35-55 years of age. The eventual aim of this work is two-fold; 1) to increase knowledge, awareness and education for individuals and clinicians about the lived experience of perimenopause and menopause through objectively measured data from digital study devices, and 2) to develop approaches to empower female individuals to manage this transition by learning what improves or worsens their symptoms.

Conditions

Perimenopause; Menopause

Keywords

Perimenopause; Menopause; Menopause Transition; Wearables; Oura; Fitbit

Outcome Measures

Primary Outcomes (2)

• Feasibility: Retention

  Proportion of participants retained according to study protocol

  From enrollment to the end of participation at 12 months

• Feasibility: Adherence

  Mean adherence to completing in-app daily study measures

  From enrollment to the end of participation at 12 months

Study Arms (4)

Main Cohort

Up to 250 participants aged 35-55 years old, residing in the US or Canada, who will be asked to complete surveys and active tasks in a study app, and use the Oura Ring Gen 4 and Fitbit Sense 2 daily. Participants will meet with research coordinators every 2 weeks to help support participation efforts and collect information on how the study and device use are going.

Hormone Sub-Cohort

A sub-cohort of up to 75 participants will be invited to participate in a hormone sub-cohort. If the participant agrees to participate in this sub-cohort, they will be asked to complete daily at-home urine hormone samples provided to them for 3 consecutive menstrual cycles. The hormone sub-cohort procedure consists of peeing on a disposable urine test strip in the morning and then using a digital analyzer to produce the results, measuring Luteinizing Hormone (LH), Estrone-3-glucuronide (E3G), and Pregnanediol Glucuronide (PdG).

Bring Your Own Device (BYOD) Open Arm

Once enrollment is complete in the main arm, and if the participant owns their own personal wearable device that includes an Oura ring, a Garmin smartwatch, Applewatch or Fitbit, they may be able to participate in the BYOD arm where they will participate by using the study app and providing the study investigators access to their wearable data. They will be asked permission for this wearable data sharing when they first download the study app during a number of opt-in screens. Up to 1000 participants may be enrolled in the BYOD arm.

Vire Clip Vasomotor Detection Sub-Cohort

A subset of up to 70 participants will be invited to participate in a vasomotor detection cohort that will involve the use of a new wearable (Vire) clip capable of capturing core body temperature through heat flow, the dynamics of respiratory effort, and skin conductance measures at multiple layers into the skin. We want to learn whether these new wearable-derived signals could be used to detect when a vasomotor event will occur, like a hot flash, night sweat, cold sweat or feelings of sudden heating. If you meet certain eligibility criteria, you will be mailed the Vire clip and given instructions on how to set it up and sync with the study app. The Vire clip is a small clip that can be clipped onto the inside of your underwear.

Eligibility Criteria

• Age: 35 Years - 55 Years
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Eligible participants will live in the US or Canada. Up to 250 participants will be invited to participate in the main cohort, 75 in the hormone sub-cohort, and 70 in the Vire clip sub-cohort.

You may qualify if:

• Are 35-55 years old
• Reside in the US or Canada
• Are able to speak, write, and read English
• Are able to provide informed consent
• Have a personally owned iPhone (iOS Version 16.4)

You may not qualify if:

• Are not willing to wear a wearable study device
• Have a hormonal intrauterine device (IUD)
• Are taking birth control pills
• Are taking systemic estrogen or progesterone
• Have been diagnosed with Polycystic ovary syndrome (PCOS)
• Are taking the following medications (cancer treatment that affects the menstrual cycle, thyroid medication)
• Have had the following procedures (hysterectomy \[removal of uterus\], bilateral, oophorectomy \[removal of both ovaries\], endometrial ablation \[surgery that destroys the lining of the uterus\])
• Are currently pregnant, attempting to conceive, recently pregnant and not yet cycling and currently breast feeding

Sponsors & Collaborators

• 4YouandMe: lead
• Steven & Alexandra Cohen Foundation: collaborator

Central Study Contacts

Sarah Goodday, PhD

CONTACT

902-237-4235; sarah@4youandme.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 14, 2026
• First Posted: May 20, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): August 31, 2027
• Study Completion (Estimated): August 31, 2027
• Last Updated: May 20, 2026

Record last verified: 2026-05